| Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 |
|---|---|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||||||
Net loss | ||||||||||
-123,156 | -708,373 | -119,172 | -352,746 | -32,348 | 15,260 | 51,170 | 127,877 | 104,635 | -76,229 | -8,504 |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||||
Depreciation and amortization | ||||||||||
3,195 | 21,974 | 31,042 | 34,837 | 34,398 | 32,238 | 7,270 | 6,231 | 6,124 | 5,767 | 2,932 |
Asset impairment charges | ||||||||||
- | - | - | 29,413 | 31,133 | 0 | 0 | - | - | 5,000 | - |
Impairment on divestiture | ||||||||||
- | - | - | 133,273 | - | - | - | - | - | - | - |
Acquired in-process research and development | ||||||||||
- | - | - | - | - | - | - | - | - | - | 21,373 |
Amortization of net premiums and discounts on available for sale securities | ||||||||||
- | - | - | - | - | -209 | -734 | -2,021 | -3,260 | -2,118 | -113 |
Amortization of long term debt financing costs | ||||||||||
- | - | - | - | - | 1,179 | 598 | 0 | 0 | - | - |
Amortization of Debt Discount (Premium) | ||||||||||
27,922 | 26,868 | 26,182 | 23,676 | 11,920 | 9,978 | 5,306 | 0 | 0 | - | - |
Unrealized foreign currency transaction losses, net | ||||||||||
57 | -2,180 | 941 | 173 | 833 | -143 | 573 | -562 | 1,217 | 0 | -580 |
Stock compensation expense | ||||||||||
18,070 | 31,520 | 30,987 | 30,605 | 34,311 | 23,078 | 14,981 | 11,017 | 8,336 | 19,437 | 22,798 |
Loss on available for sale securities | ||||||||||
- | - | - | - | - | - | - | - | - | -33 | 33 |
Deferred tax benefit | ||||||||||
0 | -89,895 | -23 | -53,292 | -5,565 | -10,272 | 30,376 | -53,246 | -43,592 | 47,737 | 1,520 |
Accretion of deferred payments | ||||||||||
3,231 | 0 | 0 | - | - | - | - | - | - | - | - |
Excess tax benefit from share-based compensation arrangements | ||||||||||
- | - | - | - | 1,443 | 7,675 | 1,558 | 9,393 | -292 | 0 | - |
Gain (Loss) on Extinguishment of Debt | ||||||||||
0 | 0 | -5,380 | 0 | 0 | - | - | - | - | - | - |
Gain on sale of business | ||||||||||
168,955 | 0 | 289,305 | 0 | 0 | - | - | - | - | - | - |
Gain on sale of assets | ||||||||||
28,582 | -105 | -521 | -543 | -35 | -39 | -69 | -299 | -293 | 0 | -33 |
Gain (Loss) on Investments | ||||||||||
-51,881 | 0 | 0 | 19,773 | 0 | 0 | - | - | - | - | - |
Gain on remeasurement of equity investment | ||||||||||
- | - | - | 22,597 | 0 | 0 | - | - | - | - | - |
Reserve for excess or obsolete inventory | ||||||||||
-390 | 17,453 | 8,533 | 42,599 | 0 | 0 | - | - | - | - | - |
Changes in contingent purchase price | ||||||||||
-258 | -18,787 | 23,981 | 20,278 | 20,823 | 16,942 | - | - | - | - | - |
Loss in equity investment | ||||||||||
- | - | - | - | -1,711 | 0 | 0 | 7,500 | 0 | 0 | - |
Adjustment to contingent purchase price | ||||||||||
- | - | - | - | - | - | 1,460 | 4,956 | -1,720 | -486 | - |
Changes in operating assets and liabilities: | ||||||||||
Accrued interest receivable | ||||||||||
- | - | - | - | - | -347 | -26 | -905 | 364 | -414 | -262 |
Accounts receivable | ||||||||||
-4,959 | -9,180 | -30,144 | -103,100 | 54,739 | 15,017 | 11,120 | 28,086 | 16,627 | -3,182 | 7,614 |
Inventory, net | ||||||||||
-2,199 | -6,511 | 15,653 | 69,318 | -5,627 | 10,130 | 31,152 | 19,794 | -701 | -2,774 | -6,890 |
Prepaid expenses and other assets | ||||||||||
-9,663 | -534 | -569 | 5,286 | 3,559 | -39 | -1,516 | 6,763 | -5,031 | 1,713 | 1,236 |
Other assets | ||||||||||
- | - | - | - | - | - | - | - | - | - | 0 |
Accounts payable | ||||||||||
-9,514 | -17,222 | -7,398 | 16,362 | -6,866 | -1,319 | 18,903 | -2,203 | 165 | -7,851 | 3,315 |
Accrued expenses | ||||||||||
-50,390 | 31,526 | -37,233 | -39,501 | 24,058 | 31,192 | -40,160 | 71,608 | -736 | 8,343 | -18,945 |
Other current liabilities | ||||||||||
-4,437 | -13,757 | 1,568 | - | - | - | - | - | - | - | - |
Payments on contingent purchase price | ||||||||||
59 | 52,543 | 1,045 | 78,900 | 0 | 0 | - | - | - | - | - |
Deferred revenue | ||||||||||
- | - | - | 8,386 | 5,257 | 3,854 | 1,685 | 125 | -616 | -8,519 | 9,588 |
Other liabilities | ||||||||||
4,272 | -7,659 | -11,446 | 549 | 3,394 | 1,335 | -265 | 171 | 62 | -28 | -4,939 |
Net cash used in operating activities | ||||||||||
-261,795 | -368,288 | -323,309 | -197,965 | 67,314 | 91,420 | 46,346 | 96,375 | 67,467 | 951 | 38,077 |
Cash flows from investing activities: | ||||||||||
Proceeds from sale of fixed assets | ||||||||||
- | - | - | 250 | 0 | 0 | - | - | - | - | 0 |
Proceeds from sale of investment | ||||||||||
- | - | - | 19,773 | 0 | 0 | - | - | - | - | - |
Purchases of available for sale securities | ||||||||||
0 | 131,560 | 0 | - | - | - | 65,354 | 33,583 | 128,240 | 133,700 | 161,822 |
Proceeds from sale of assets | ||||||||||
12,672 | 0 | 0 | - | - | - | - | - | - | - | - |
Proceeds from maturities and sales of available for sale securities | ||||||||||
0 | 131,535 | 0 | - | - | 50,656 | 38,881 | 126,713 | 108,640 | 161,646 | 161,505 |
Purchases of fixed assets | ||||||||||
7 | 4,525 | 2,176 | 2,555 | 7,289 | 13,574 | 1,005 | 1,269 | 340 | 342 | 19,395 |
Payments for intangible assets | ||||||||||
0 | 0 | 10,000 | 112,617 | 15,000 | 0 | 36,678 | 7,000 | 0 | 0 | 2,000 |
Other investments | ||||||||||
- | - | - | - | 3,625 | -1,125 | 2,500 | - | - | - | - |
Investment in pharmaceutical company | ||||||||||
- | - | - | - | - | - | - | - | - | - | 5,000 |
Acquisition of business, net of cash acquired | ||||||||||
- | - | - | 28,397 | 58,934 | 542,579 | 0 | 0 | - | 37,168 | 23,534 |
Proceeds from Divestiture of Businesses | ||||||||||
166,383 | 0 | 437,875 | 0 | 0 | - | - | - | - | - | - |
Adjustment to goodwill | ||||||||||
- | - | - | - | - | - | - | - | 263 | 0 | - |
Change in restricted cash | ||||||||||
- | - | - | -35 | -92 | -11 | -3,148 | -1,049 | -1,278 | 1,652 | - |
Other investing activities | ||||||||||
- | - | - | - | - | - | - | 0 | - | - | - |
Net cash provided by investing activities | ||||||||||
179,048 | -4,550 | 425,699 | -123,511 | -84,756 | -504,361 | -63,508 | 78,410 | -18,399 | -11,216 | -50,246 |
Cash flows from financing activities: | ||||||||||
Proceeds from issuances of common stock, net | ||||||||||
15,608 | 48,621 | 33,776 | 95,198 | 17,343 | 74,212 | 22,935 | 6,725 | 3,361 | 1,804 | 5,542 |
Payments on contingent purchase price | ||||||||||
511 | 10,523 | 9,404 | 157,601 | 9,953 | 0 | 0 | - | - | - | - |
Proceeds from equity offering, net | ||||||||||
- | - | - | - | - | 189,600 | 0 | - | - | - | - |
Purchase of treasury stock | ||||||||||
- | - | - | - | - | - | 50,000 | 0 | 0 | - | - |
Proceeds from the issuance of convertible senior notes | ||||||||||
163,000 | 0 | 402,500 | 400,000 | 0 | 0 | 275,000 | 0 | 0 | - | - |
Repayments of Long-term Debt | ||||||||||
0 | 55,000 | 323,225 | 0 | 0 | - | - | - | - | - | - |
Purchase of capped call transactions related to convertible senior notes | ||||||||||
0 | 0 | 33,931 | 0 | 0 | - | - | - | - | - | - |
Proceeds from settlement of bond hedges related to convertible senior notes | ||||||||||
0 | 0 | 100,459 | 0 | 0 | - | - | - | - | - | - |
Settlement of warrants | ||||||||||
0 | 2 | 87,874 | 0 | 0 | - | - | - | - | - | - |
Proceeds from issuance of warrants | ||||||||||
- | - | - | - | - | - | 38,425 | 0 | 0 | - | - |
Purchase of convertible note hedge | ||||||||||
- | - | - | - | - | - | 58,223 | 0 | 0 | - | - |
Debt issuance costs | ||||||||||
5,464 | 0 | 11,725 | 12,769 | 0 | 0 | 8,774 | 0 | 0 | - | - |
Purchase of shares of non-controlling interest | ||||||||||
0 | 167 | 0 | 0 | - | - | - | - | - | - | - |
Excess tax benefit from share-based compensation arrangements | ||||||||||
- | - | - | - | 1,443 | 7,675 | 1,558 | 9,393 | 0 | 0 | - |
Net cash provided by financing activities | ||||||||||
172,633 | -17,071 | 70,576 | 324,828 | 8,833 | 271,487 | 220,921 | 16,118 | 3,361 | 1,804 | 5,542 |
Effect of exchange rate changes on cash | ||||||||||
-1,766 | -58 | -700 | -920 | 2,623 | -1,265 | 305 | -1,885 | 1,710 | -332 | -482 |
Increase (decrease) in cash, cash equivalents and restricted cash | ||||||||||
88,120 | -389,967 | 172,266 | 2,432 | -5,986 | -142,719 | 204,064 | 189,018 | 54,139 | -8,793 | -7,109 |
Supplemental disclosure of cash flow information: | ||||||||||
Interest paid | ||||||||||
21,069 | 22,561 | 12,269 | 8,837 | 3,782 | 4,374 | 1,786 | 0 | 0 | - | - |
Taxes paid | ||||||||||
581 | 575 | 36 | 114 | 1,371 | 9,137 | 1,709 | 6,850 | 1,699 | 358 | 2,518 |
Non-cash investing and financing activities | ||||||||||
Issuance of common stock upon conversion of convertible notes | ||||||||||
0 | 32,018 | 0 | 0 | - | - | - | - | - | - | - |
Receipt of common stock upon settlement of 2017 Note hedge | ||||||||||
0 | 40,015 | 0 | 0 | - | - | - | - | - | - | - |
Issuance of common stock upon the exercise of the 2017 Warrants | ||||||||||
0 | 1,638 | 0 | 0 | - | - | - | - | - | - | - |
Reconciliation of cash, cash equivalents and restricted cash | ||||||||||
Fixed asset additions included in current liabilities | ||||||||||
- | - | - | - | - | - | - | - | - | - | 6,327 |